Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Stock Quote Today & Recent News Prothena Corporation plc PRTA

Healthcare Biotechnology
Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. Its product pipeline include Prasinezumab, an investigational humanized monoclonal antibody which is in phase 2b clinical trial, as well as phase 1 and 2 clinical trials for the treatment of... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (NDAQ:PRTA)

Prothena Announces Board of Directors Update

Business Wire December 12, 2025

Prothena Announces Poster Presentation on its TDP-43 CYTOPE® Program at Neuroscience 2025

Business Wire November 19, 2025

Prothena Highlights Phase 2 Data for Coramitug (Formerly PRX004) Published in Circulation, Official Journal of AHA

Business Wire November 11, 2025

Prothena Reports Third Quarter 2025 Financial Results and Business Highlights

Business Wire November 6, 2025

Prothena to Report Third Quarter 2025 Financial Results on November 6

Business Wire October 30, 2025

Prothena's Partner Bristol Myers Squibb Obtains Fast Track Designation from the U.S. FDA for BMS-986446 (PRX005), an Anti-MTBR-Tau-Targeting Antibody, for the Treatment of Alzheimer's Disease

Business Wire October 1, 2025

Prothena to Participate in the Cantor Fitzgerald Global Healthcare Conference

Business Wire August 28, 2025

Prothena Provides Update on PRX012 and Announces Results from the Phase 1 ASCENT Clinical Program

Business Wire August 27, 2025

Prothena Announces that Novo Nordisk Will Advance Coramitug (Formerly PRX004) into Phase 3 Development for ATTR Amyloidosis with Cardiomyopathy

Business Wire August 6, 2025
View More News ››

Opinion & Analysis (NDAQ:PRTA)

How sick will Brexit make biotech and pharma?

The Life Sciences Report June 29, 2016
View More Opinion ››

Bullboard Posts (NDAQ:PRTA)

Prothena (PRTA): A Promising Biotech Poised for Transformati

http://beyondspx.com/2024/07/31/prothena-prta-a-promising-biotech-poised-for-transformative-breakthroughs/
MikeTester - August 2, 2024
View more Bullboard ››

Playboy Inc.

Playboy Inc.

Playboy, Inc. operates as a pleasure and leisure company in the United States, Australia, China, the United Kingdom, and ...
View More »

Podcasts